{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-039171","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.537851+00:00","generated_at":"2026-06-15T01:24:05.741219+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Blue Water Biotech Q1 net loss $2.8M, cash $20.3M, ENTADFI acquisition closed","bullets":["Net loss of $2.8M in Q1 2023 vs $2.1M in Q1 2022; cash $20.3M, down from $25.8M at Dec 2022.","Acquired ENTADFI (FDA-approved BPH treatment) for up to $100M; $20M upfront payable in tranches through Sep 2024.","Appointed Frank Jaeger as SVP Marketing & Business Development for ENTADFI launch; Timothy Ramdeen joined board.","Partnered with AbVacc to develop vaccine candidates targeting monkeypox and Marburg using norovirus VLP platform.","Signed research agreement with UT Health San Antonio for non-human primate study of Chlamydia vaccine BWV-401."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-039171","json":"https://secwatch.observer/filing/0001213900-23-039171.json","markdown":"https://secwatch.observer/filing/0001213900-23-039171.md","text":"https://secwatch.observer/filing/0001213900-23-039171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023039171/0001213900-23-039171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023039171/ea178509-8k_bluewater.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:24:05.741219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}